CCDC22 deficiency in humans blunts activation of proinflammatory NF-kappa B signaling

NF-kappa B is a master regulator of inflammation and has been implicated in the pathogenesis of immune disorders and cancer. Its regulation involves a variety of steps, including the controlled degradation of inhibitory I kappa B proteins. In addition, the inactivation of DNA-bound NF-kappa B is essential for its regulation. This step requires a factor known as copper metabolism Murr1 domain-containing 1 (COMMD1), the prototype member of a conserved gene family. While COMMD proteins have been linked to the ubiquitination pathway, little else is known about other family members. Here we demonstrate that all COMMD proteins bind to CCDC22, a factor recently implicated in X-linked intellectual disability (XLID). We showed that an XLID-associated CCDC22 mutation decreased CCDC22 protein expression and impaired its binding to COMMD proteins. Moreover, some affected individuals displayed ectodermal dysplasia, a congenital condition that can result from developmental NF-kappa B blockade. Indeed, patient-derived cells demonstrated impaired NF-kappa B activation due to decreased I kappa B ubiquitination and degradation. In addition, we found that COMMD8 acted in conjunction with CCDC22 to direct the degradation of I kappa B proteins. Taken together, our results indicate that CCDC22 participates in NF-kappa B activation and that its deficiency leads to decreased I kappa B turnover in humans, highlighting an important regulatory component of this pathway